Allogene Therapeutics, Inc.

NASDAQ:ALLO

Biotechnology

Healthcare
$0.70 +1.02%

+$0.02 today

Market cap
$241.11M
Beta
0.46
P/E (TTM)
-2.7
EPS (TTM)
-$0.72
52W Low $0.98High $4.46

Volume 10.55M

Average 10.19M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$149.25M

FY 2025 · Annual

Investing Cash Flow

$95.56M

FY 2025 · Annual

+26.3% YoY

Financing Cash Flow

$30.16M

FY 2025 · Annual

-74.2% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(257.01M)(332.63M)(327.27M)(257.59M)(190.89M)
Depreciation & Amortization10.45M14.3M14.2M13.64M12.36M
Deferred Income Tax10.4M8.08M0443K0
Stock-Based Compensation80.82M83.6M65.95M51.74M37.64M
Change in Working Capital(32.09M)3.71M(15.31M)(24.8M)(10.88M)
Accounts Receivables00000
Inventory00000
Accounts Payables(767K)4.87M(7.5M)(503K)(1.23M)
Other Working Capital(31.32M)(1.16M)(7.8M)(24.3M)(9.65M)
Other Non-Cash Items2.61M2.43M24.69M16.26M2.52M
Operating Cash Flow(184.81M)(220.52M)(237.73M)(200.3M)(149.25M)
Capital Expenditures(21.45M)(5.19M)(1.52M)(694K)(386K)
Acquisitions (Net)(17.71M)(111.35M)000
Purchases of Investments(525.58M)(248.11M)(438.63M)(361.48M)(138.26M)
Sales of Investments728.39M359.46M603.43M437.86M234.2M
Other Investing Activities0111.35M000
Investing Cash Flow163.66M106.16M163.29M75.69M95.56M
Debt Repayment00000
Common Stock Issued11.96M2.95M91.11M114.4M23.25M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities004.58M2.28M6.91M
Financing Cash Flow11.96M2.95M95.7M116.68M30.16M
Effect of Forex Changes00000
Net Change in Cash(9.19M)(111.41M)21.25M(7.94M)(23.53M)
Free Cash Flow(206.26M)(225.71M)(239.25M)(200.99M)(149.63M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$190.9M
+ D&A$12.4M
+ Stock-Based Comp$37.6M
+ Deferred Tax$0
- Working Capital-$10.9M
+ Other Non-Cash$2.5M
= Operating Cash Flow-$149.2M
- Capex-$386.0K
= Free Cash Flow-$149.6M

Analysis

FY2025 free cash flow is -$149.6M. FCF conversion is 78.4% of net income. Operating cash flow was -$149.2M, with capex of -$386.0K. The largest bridge item is Stock-Based Comp at $37.6M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13GSC 13G filingNov 10, 2026
10-QQuarterly reportNov 6, 2026
8-KCurrent reportNov 5, 2026
SC 13G/ASC 13G/A filingOct 27, 2026
4Statement of changes in beneficial ownershipOct 23, 2026

Does ALLO generate free cash flow?

Allogene Therapeutics, Inc. (ALLO) generated -$149.63M of free cash flow in fiscal 2025.

How much operating cash flow does ALLO produce?

Operating cash flow was -$149.25M, before capital expenditures of $386,000.00.